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Background: With the irrational and massive use of
Antibiotics in underdeveloped and developing countries,
resultantly there was increased Resistance to Antibiotics
and with the increased interest in herbal medicine and use
of honey for various therapeutic purposes has led to the
search for new antibacterial honeys. Hence a study was con-
ducted to assess the antibacterial and fungicidal activity of
six honeys locally produced under natural and farm environ-
ment and their comparison with the commercially available
therapeutic honeys (including Medihoney® and rewa rewa
honey).
Methods: An agar dilution method was used to assess the
activity of honeys against 15 bacteria and one yeast. The
honeys were tested at eight concentrations ranging from 1%
to 50%.
Results: All 15 bacteria were inhibited by all honeys used
in this study with only the yeast Candida albicans not inhib-
ited by the honeys at 20%. Little antibacterial activity was
seen at honey concentrations <5%, with minimal inhibition
at 5%. No honey was able to produce complete inhibition
of bacterial growth at concentration up to 20% but with the
increase in concentration 40% honey obtained from wild bee
produces remarkable inhibition. Although Medihoney® and
rewa rewa had the overall good activity but the activity of
naturally produced (by wild bee) local honey was even better
than those. But the locally produced honeys by commercial
beekeepers had poor inhibitory activity for some, but not
for all bacteria.
Conclusions: Honeys other than those commercially
available as antibacterial honeys can have equivalent
antibacterial activity if they produced through hygienic
methods. The newly identiﬁed antibacterial honeys may
prove to be a valuable source of future therapeutic
honeys.
doi:10.1016/j.ijid.2008.05.1061
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Background: Tigecycline, a novel glycylcycline class
agent (ﬁrst in class), has been utilized for serious multidrug-
resistant (MDR) pathogen infections in several global
locations for 1—3 years. This prospective in vitro multi-
center trial evaluates nearly 4,000 pathogens from Japan
(2006—2007).
Methods: A total of 3,902 isolates (19 medical centers)
were processed by reference broth microdilution methods
in a single central laboratory. CLSI methods were applied
and breakpoints found in CLSI M100-S18 (2008) or USA-
FDA Tygacil® package insert were used. The most prevalent
organisms were: S. aureus (SA; 1,198), S. pneumoniae (SPN;
459), E. coli and Klebsiella (199 each), CoNS (198), Enter-
obacters (197), enterococci (195) and Acinetobacters (193).
All concurrent QC was acceptable.
Results: Against Gram-positive cocci, tigecycline MIC50/90
values were: SA (0.12/0.5mg/L), enterococci and CoNS
(0.12/0.25), SPN (≤0.03/0.06), and -haemolytic (BHS) or
viridans group streptococci (≤0.03/0.06); all susceptible
except 3 MRSA (MIC at 1mg/L). Among Enterobacteri-
aceae, tigecycline inhibited 100.0, 99.0 and 100.0% of
E. coli, Klebsiella and Enterobacters at ≤2mg/L, respec-
tively. P. mirabilis and S. marcescens were less susceptible
to tigecycline (MIC90 range, 1 to 4mg/L). Acinetobac-
ters (193) had MIC values ranging to 4mg/L; 99.0% at
≤2mg/L and 1.6% carbapenem-resistant. P. aeruginosa were
generally tigecycline-resistant (MIC90, >4mg/L). 14.5% of
group B were levoﬂoxacin-resistant (clonal with multi-
ple QRDR mutations in 7 sites). ESBL rates were only
2.0—6.5% in E. coli and Klebsiella, and ﬂuoroquinolones
and trimethoprim/sulfamethoxazole resistances were high-
est (20.1—21.1%) in E. coli.
Conclusions: Tigecycline was observed to be active
against nearly all tested species from Japanese medical
centers for year 2003—2004 strains, and in this prospective
sample report remains similarly active (2006—2007 isolates).
Resistant subsets (MRSA, ESBL enteric bacilli, MDR Acine-
tobacters) were generally inhibited at USA-FDA-susceptible
breakpoints for tigecycline. Possible use of tigecycline
for some serious MDR infections in Japan should be
considered.
doi:10.1016/j.ijid.2008.05.1062
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Background: Development of antibiotic resistance is one
of the most common problems in medicine. Thus, discover-
ing of new antibacterial compounds is interesting. Marine
algae are rich sources of bioactive metabolites that could
be effective as antimicrobial agents. The aim of this in-vitro
